Cardiff Oncology
CRDF
55 hedge funds and large institutions have $7.84M invested in Cardiff Oncology in 2023 Q4 according to their latest regulatory filings, with 7 funds opening new positions, 8 increasing their positions, 14 reducing their positions, and 7 closing their positions.
29% more call options, than puts
Call options by funds: $62K | Put options by funds: $48K
3% more capital invested
Capital invested by funds: $7.58M → $7.84M (+$252K)
0% more funds holding
Funds holding: 55 → 55 (0)
0% more first-time investments, than exits
New positions opened: 7 | Existing positions closed: 7
0.2% less ownership
Funds ownership: 12.05% → 11.85% (-0.2%)
43% less repeat investments, than reductions
Existing positions increased: 8 | Existing positions reduced: 14
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
MCM
MAI Capital Management
Independence,
Ohio
|
+$187K |
| 2 |
XT
XTX Topco
George Town,
Cayman Islands
|
+$40.5K |
| 3 |
Geode Capital Management
Boston,
Massachusetts
|
+$38.5K |
| 4 |
Citadel Advisors
Miami,
Florida
|
+$33.6K |
| 5 |
Jane Street
New York
|
+$26.2K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Assenagon Asset Management
Senningerberg,
Luxembourg
|
-$117K |
| 2 |
Jacobs Levy Equity Management
Florham Park,
New Jersey
|
-$91.1K |
| 3 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$69.4K |
| 4 |
Renaissance Technologies
New York
|
-$45.5K |
| 5 |
Creative Planning
Overland Park,
Kansas
|
-$40.2K |
CRDF Hedge Fund Activity: Q4 2023 in Review
55 of the 6,869 institutional investors tracked by Wall St. Rank reported a position in Cardiff Oncology (CRDF) for Q4 2023, worth a combined $7.84M — up 3.3% from $7.58M a quarter earlier.
Fund positioning in CRDF was balanced in Q4 2023: 7 funds opened new positions, 7 closed out, 8 added to existing stakes and 14 trimmed.
The largest buyer was MAI Capital Management, adding an estimated $187K. The largest seller was Assenagon Asset Management, exiting entirely with an estimated $117K sold.
- 55 institutional investors held Cardiff Oncology (CRDF) as of Q4 2023, unchanged from Q3 2023.
- Funds reported $7.84M of Cardiff Oncology stock for Q4 2023, up 3.3% quarter-over-quarter.
- 7 funds opened new Cardiff Oncology positions in Q4 2023 and 7 closed out, a net change of 0 holders.
- The largest Cardiff Oncology buyer in Q4 2023 was MAI Capital Management, an estimated $187K added.
- The largest Cardiff Oncology seller in Q4 2023 was Assenagon Asset Management, an estimated $117K sold.
Based on aggregated 13F filings for Q4 2023.